PubMed: Framework for the Design of Cannabis-Mediated Phase I Drug-Drug Interaction Studies

PubMed: Framework for the Design of Cannabis-Mediated Phase I Drug-Drug Interaction Studies

Curr Rev Clin Exp Pharmacol. 2021 Aug 13. doi: 10.2174/2772432816666210813123716. Online ahead of print.

ABSTRACT

Cannabis has become legal in much of the United States similarly to many other countries, for either recreational or medical use. The use of cannabis products is rapidly increasing while the body of knowledge of its myriad of effects still lags. In vitro and clinical data show that cannabis’ main constituents, delta-9-tetrahydrocannabinol and cannabidiol, can affect the pharmacokinetics (PK), safety and pharmacodynamics (PD) of other drugs. Within the context of clinical drug development, the widespread and frequent use of cannabis products has essentially created another special population; that is, the cannabis user. We propose that all clinical drug development programs include a Phase 1 study to assess the drug-drug interaction potential of cannabis as a precipitant on the PK, safety and if applicable, the PD of all new molecular entities (NMEs) in a combination of healthy adult subjects as well as frequent and infrequent cannabis users. This data should be required to inform drug labeling and aid health care providers in treating any patient, as cannabis has quickly become another common concomitant medication and cannabis users, a new special population.

PMID:34455952 | DOI:10.2174/2772432816666210813123716

#CBD #Hemp https://pubmed.ncbi.nlm.nih.gov/34455952/?utm_source=Chrome&utm_medium=rss&utm_campaign=None&utm_content=1jYCQzi_o_qLYr-oQfnMhShgOXkvGma3vcnBGJtrBhuJMOvEVJ&fc=None&ff=20210830065921&v=2.14.5 August 30, 2021 10:00 am

Click to SAVE as a PDF ...... Click to PRINT